REAP Financial Group LLC Acquires 317 Shares of Boston Scientific Corporation $BSX

REAP Financial Group LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 179.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 494 shares of the medical equipment provider’s stock after purchasing an additional 317 shares during the quarter. REAP Financial Group LLC’s holdings in Boston Scientific were worth $53,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Venturi Wealth Management LLC boosted its stake in Boston Scientific by 8.0% in the 2nd quarter. Venturi Wealth Management LLC now owns 8,866 shares of the medical equipment provider’s stock worth $952,000 after purchasing an additional 654 shares during the period. BankPlus Trust Department boosted its position in shares of Boston Scientific by 21.2% during the 2nd quarter. BankPlus Trust Department now owns 10,171 shares of the medical equipment provider’s stock valued at $1,092,000 after acquiring an additional 1,776 shares during the last quarter. High Note Wealth LLC boosted its position in shares of Boston Scientific by 9.3% during the 2nd quarter. High Note Wealth LLC now owns 13,642 shares of the medical equipment provider’s stock valued at $1,465,000 after acquiring an additional 1,158 shares during the last quarter. SGL Investment Advisors Inc. bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $326,000. Finally, Shell Asset Management Co. boosted its position in shares of Boston Scientific by 72.3% during the 2nd quarter. Shell Asset Management Co. now owns 35,233 shares of the medical equipment provider’s stock valued at $3,784,000 after acquiring an additional 14,779 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on BSX shares. Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Finally, Wells Fargo & Company raised their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Stock Performance

BSX stock opened at $96.73 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $102.34 and its two-hundred day simple moving average is $101.96. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The firm has a market cap of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.31 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm posted $0.62 earnings per share. The business’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.